<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444390</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0105/1403</org_study_id>
    <nct_id>NCT02444390</nct_id>
  </id_info>
  <brief_title>Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor</brief_title>
  <acronym>SAFIR-TOR</acronym>
  <official_title>Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective biomarker study to show that p4EBP1 staining predicts clinical benefit
      from treatment with everolimus in patients who are eligible for everolimus+exemestane
      treatment. This trial is not aimed at evaluating a drug activity. Everolimus and exemestane
      are prescribed within their approved indication as per usual practice and are not part of
      this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogen hormone receptor-positive metastatic breast cancer who failed to non steroidal
      aromatases inhibitors in patients who are eligible for everolimus+exemestane treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the predictive value of p4EBP1 for an mTOR inhibitor efficacy</measure>
    <time_frame>from inclusion up to 6 months</time_frame>
    <description>The primary endpoint of the trial is the predictive value of p4EBP1 for an mTOR inhibitor efficacy, measured by the association between expression level of the biomarker (high vs low expression with a cutoff value set at the median percentages of marked cells) and clinical benefit after 6 months of everolimus+exemestane treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane+everolimus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Exemestane+everolimus are administered as per their approved indication</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>biopsy of a metastasis</description>
    <arm_group_label>Exemestane+everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for everolimus+exemestane treatment as required by the marketing
             authorisation conditions

               1. Women (or men) with histologically-proven ER+ and/or PR+ /HER2- metastatic breast
                  adenocarcinoma or locally advanced disease who cannot be treated with surgery
                  and/or radiation therapy

               2. postmenopausal women

               3. asymptomatic if visceral disease

               4. second line hormonotherapy or more for metastatic or locally advanced disease
                  after recurrence or progression following a non-steroidal aromatase inhibitor (in
                  adjuvant or metastatic setting)

                  Eligible for the biopsy

               5. Progressive disease under endocrine therapy at the time of inclusion

               6. Treatment with everolimus and exemestane not yet started

               7. Patients with metastases that can be biopsied, except bone metastases

               8. Measurable or evaluable disease

               9. Age ≥ 18 years

              10. WHO Performance Status 0/1

              11. Provision of signed and dated, written informed consent prior to any protocol
                  specific procedure, including biopsy

              12. Patient with social insurance coverage

        Exclusion Criteria:

          -  1. Contraindications for everolimus+exemestane treatment 2. Previous treatment with an
             anti-mTOR therapy 3. More than 1 previous line of chemotherapy in metastatic setting
             4. Life expectancy &lt;3 months, 5. Spinal cord compression and/or symptomatic or
             progressive brain metastases (unless asymptomatic or treated and stable off steroids
             for at least 30 days prior to start of study drug).

             6. Haematopoietic function or organ impairment as shown by the following criteria:

               -  Polynuclear neutrophils &lt; 1.5 x 109/L

               -  Platelets &lt; 100 x 109/L

               -  Haemoglobin &lt; 90 g/L

               -  ALAT/ASAT &gt; 2.5x ULN in the absence of or &gt; 5x ULN in the presence of liver
                  metastases

               -  bilirubin &gt; 1.5xULN

               -  creatinine clearance ≤50 mL/min (measured or calculated by Cockroft and Gault
                  formula)

               -  calcium and phosphate &gt; ULN 7. Abnormal coagulation or any other medical
                  situation contraindicating biopsy 8. Bone metastases when this is the only site
                  of biopsiable disease 9. Any condition which in the Investigator's opinion makes
                  it undesirable for the subject to participate in the trial or which would
                  jeopardize compliance with the protocol.

                  10. Individuals deprived of liberty or placed under the authority of a tutor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bachelot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, Lyon, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Bachelot, MD</last_name>
    <email>thomas.bachelot@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Jimenez</last_name>
    <email>m-jimenez@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, MD</last_name>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario Campone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale Dubray-Longeras, MD</last_name>
      <email>pascale.dubray-longeras@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Dubray-Longeras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Bachelot, MD</last_name>
      <email>thomas.bachelot@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Bachelot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest/Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, MD</last_name>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario Campone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc Ferrero, MD</last_name>
      <email>jean-marc.ferrero@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Cottu, MD</last_name>
      <email>paul.cottu@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Paul Cottu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Claire Hardy-Bessard, MD</last_name>
      <email>ac.hardy@clin-armoricaine.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Claire Hardy-Bessard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE Lucien Neuwirth</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe JACQUIN, MD</last_name>
      <email>jean-philippe.jacquin@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Philippe JACQUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PETIT, MD</last_name>
      <email>tpetit@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry PETIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Dalenc, MD</last_name>
      <email>dalenc.florence@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Dalenc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth LUPORSI, MD</last_name>
      <email>e.luporsi@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth LUPORSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arnedos</last_name>
      <email>Monica.ARNEDOS@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Monica Arnedos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice André, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Failed non steroidal aromatases inhibitors</keyword>
  <keyword>Eligible for everolimus+exemestane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

